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Abstract
Background: Newcastle disease (ND) and avian influenza subtype H9N2 (H9N2 AI) are two of the most important
diseases of poultry, causing severe economic losses in the global poultry industry. Vaccination is an effective way to
prevent and control the spread of ND virus (NDV) and H9N2 AI virus (AIV), but the antigenic differences between
the current circulating strains and the vaccine strains might account for recent ND and H9N2 AI outbreaks in
vaccinated poultry flocks.
Methods: We developed an inactivated bivalent H9N2 and NDV vaccine based on the current prevalent strains of
H9N2 AIV and NDV in China and evaluated its efficacy in chickens in this study.
Results: The results indicated that the inactivated bivalent vaccine could induce a fast antibody response in vaccinated
chickens. The hemagglutination inhibition (HI) titer in the sera increased rapidly, and the highest HI titer was observed
at 4 weeks post-vaccination (wpv) with a mean titre of 8.6 log2 for NDV and 9.5 log2 for H9N2. Up until 15 wpv, HI
titers were still detectable at a high level of over 6 log2. The immunized chickens showed no signs of disease after
challenge at 3 wpv with the prevalent strains of NDV and H9N2 AIV isolated in 2012–2014. Moreover, viral shedding
was completely inhibited in vaccinated chickens after challenge with H9N2 AIV and inhibited by at least 90% with NDV
compared to the controls at 5dpc.
Conclusions: Our findings suggest that the inactivated NDV and H9N2 vaccine induces a fast and strong antibody
response in vaccinated chickens and is efficacious in poultry against NDVs and H9N2 AIVs.
Keywords: Newcastle disease virus, H9N2 avian influenza virus, Inactivated vaccine, Efficacy, Chicken
Background
Newcastle disease virus (NDV) and avian influenza virus
(AIV) are two of the most important pathogens in
poultry worldwide [1]. Newcastle disease (ND) is usually
caused by virulent NDV, which can result in 100% mortal-
ity in many species of birds [2]. The H9N2 low pathogenic
avian influenza viruses have been circulating worldwide in
multiple avian species, resulting in great economic losses
owing to reduced egg production or increased mortality
associated with coinfection with other pathogens [3–6].
Thus, severe economic losses in the poultry industry
caused by NDV and AIV highlight the importance of
vaccine improvement and development.
In China, the implementation of extensive vaccination
programs in commercial poultry farms has reduced the
number of epizootic outbreaks of ND in recent years.
However, genotype VII NDV strains of class II have
remained a constant threat to domestic poultry since the
2000s and most recent Chinese isolates belong to a sub-
lineage of genotype VIId [7–9]. The predominance of
genotype VIId in China is similarly observed in other
countries in Asia and the Middle East, including Iran
[10], Qatar [11], Japan [12], Korea [13], Kazakhstan [14],
Vietnam [15], Pakistan [16], Israel [17], and Malaysia
[18, 19]. In a previous study, we genotypically character-
ized the NDV isolates recovered from chickens between
2005 and 2012 to establish the nature of the circulating
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genotype VII strains in China [20]. Our results indicated
that genotype VIId strains were at least 95.1% identical
at the nucleotide level across the whole genome. How-
ever, they showed only 82–83% nucleotide sequence
identity with vaccine strains LaSota and B1. These vac-
cine strains belong to genotype II in class II and were
isolated 60 years ago. The outbreaks of ND in vaccinated
poultry flocks in recent years are mainly attributed to
the significant differences in the biology, serology, and
genetics of the predominant circulating NDV strains
compared with the current vaccine strains [8].
On the basis of clade classification, 69 genotypes were
detected among H9N2 chicken viruses isolated in China
from 1994 to 2013 [21]. In contrast, most of the 2010–
2014 viruses belonged to a single G57 genotype, which
was first detected in chickens in Jiangxi and Jiangsu
Provinces in 2007, and its prevalence increased sharply
during 2009. Since 2010, it has been the predominant
genotype in circulation throughout China. This genotype
was generated by continued reassortment that can be
traced back to the year 1994. The neuraminidase gene
was derived from the A/chicken/Beijing/1/1994-like
lineage. Since the late 1990s, vaccination has been
carried out in China to prevent and control H9N2 AIV
infection in chicken flocks [21]. However, commercial
vaccines did not provide complete protection against
endemic H9N2 AIVs [22].
In this study, we developed an inactivated H9N2 and
NDV vaccine based on a H9N2 A/chicken/Hebei/G/2012
(G) virus and a ND Chicken/Shandong/aSG10/2010
(aSG10) attenuated virus that are closely related to
the current endemic strains of H9N2 and ND virus
in China and evaluated its efficacy in chickens.
Results
Challenge virus
Based on phylogenetic analysis of the NDV F gene, three
NDV isolates were selected as challenge strains in this
study: Chicken/China/Hebei/01/2012 (HB12), Chicken/
China/Shandong/01/2013 (SD13) and Chicken/China/
Hebei/01/2014 (HB14) (Table 1 and Fig. 1a). All three
viruses were characterized as virulent strains based on
the multiple basic amino acid motif of the fusion (F)
cleavage site 112RRQKR↓F117 and classified as genotype
VII NDV, which showed high genetic variation with the
genotype II LaSota vaccine.
Based on phylogenetic analysis of the H9N2 AIV
hemagglutinin (HA) gene, three H9N2 isolates were se-
lected as challenge strains in the study: A/Chicken/
Jiangsu/03/2012 (JS12), A/Chicken/Hebei/03/2013 (HB13),
and A/Chicken/Shandong/03/2014 (SD14) (Table 1 and
Fig. 1b). All three viruses were characterized as LPAI
H9N2 strains, which had a PSRSSR↓GLF motif in the
HA gene cleavage site. Even though these three vi-
ruses and the traditional Chinese vaccine strains (A/
chicken/Guangdong/SS/94, A/chicken/Shandong/6/96 and
A/chicken/Shanghai/F/98) belonged to the same lineage
BJ/94, there was a high degree of genetic variation among
them. Lineage BJ/94 was further divided into three sub-
groups: I, II, and III. Of 19 H9N2 AIVs isolated between
2012 and 2014, all belonged to subgroup III and the
Chinese vaccine strains belonged to group I.
Biological characterization of the viruses
The pathogenicity of vaccine candidates and challenged
strains was evaluated using the intracerebral pathogenicity
index (ICPI) test in 1-day-old specific-pathogen-free (SPF)
chickens and the intravenous pathogenicity index (IVPI)
test in 6-week-old SPF chickens, the results are shown in
Table 1. The ICPI value of the NDV vaccine strain aSG10
was 0.25, categorizing it as an avirulent (lentogenic) strain,
whereas the ICPI values of the NDV challenge strains
were 1.89-1.98, categorizing them as highly virulent (velo-
genic) strains. The IVPI value of the H9 AIV vaccine strain
G was 0.50, whereas the IVPI values of the H9 AIV chal-
lenge strains were 0.30-0.50, classifying them as low
pathogenic AIV strains. The egg infective dose 50 (EID50)
values of the three NDV isolates were between 8.5 log10
Table 1 Characterization of NDV and H9 AIV strains
Group Strains Abbreviation Country (province) Host ICPIa IVPIb Genotype EID50/0.1 mL
NDV Chicken/Shandong/aSG10/2010 aSG10 China (Shandong) Layer 0.25 ND VII 109.30
Chicken/China/Hebei/01/2012 HB12 China (Hebei) Broiler 1.96 ND VII 108.50
Chicken/China/Shandong/01/2013 SD13 China (Shandong) Broiler 1.89 ND VII 109.30
Chicken/China/Hebei/01/2014 HB14 China (Hebei) Layer 1.98 ND VII 109.30
AIV A/chicken/Hebei/G/2012 G China (Hebei) Broiler ND 0.50 BJ/94 (III) 109.00
A/Chicken/Jiangsu/03/2012 JS12 China (Jiangsu) Broiler ND 0.30 BJ/94 (III) 108.00
A/Chicken/Hebei/03/2013 HB13 China (Hebei) Layer ND 0.35 BJ/94 (III) 108.00
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EID50/0.1 mL and 9.3 log10 EID50/0.1 mL, and for the
H9N2 viruses were between 7.5 log10 EID50/0.1 mL and
8.0 log10 EID50/0.1 mL.
Inactivation confirmation of the viruses
To confirm the complete inactivation of two viruses, the
formalin-treated viruses were performed three passages
in 10-day-old embryonated SPF chicken eggs. All
chicken embryos injected with formalin-treated viruses
survived after 120 h, and no HA titer was detected.
Dynamics of the HI antibody
To determine the dynamics of the HI antibody in immu-
nized birds, serum was collected from vaccinated
chickens weekly and subjected to a HI test. The antibody
titer increased rapidly after inoculation of the inactivated
vaccine, and the mean HI titer reached 6.9 log2 against
NDV and 7.8 log2 against H9N2 antigen at 2 wpv. The
highest HI titer was observed at 4 wpv, with a mean log2
HI titer of 8.6 for NDV and 9.5 for H9N2. Up until 15
wpv, HI titers were still detectable at a high level, with a
mean HI titer of 6.7 log2 against NDV and 6.0 log2
against H9N2 (Fig. 2).
Protective efficacy against virulent NDV
To evaluate the efficacy of the inactivated vaccine
against virulent NDV, three genotype VII NDVs were
selected for a challenge test. About 24 h post-
Fig. 1 Phylogenetic tree of F genes of NDV (a) and HA genes of H9N2 influenza viruses (b). Unrooted phylogenetic trees were generated using
the distance-based neighbor-joining method and MEGA 5.1 software. Statistical support for tree branches was assessed by bootstrap analysis
using 1000 replications; numbers above branches indicate neighbor-joining bootstrap values that were≥ 70%; the tree is drawn to scale, with
branch lengths measured in the number of substitutions per site. Analysis was based on nucleotides of the F genes of NDV and HA genes of
H9N2. The arrow indicates vaccine candidates, black triangles indicate the NDV viruses used for challenge, black circles indicate the H9 viruses
used for challenge
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challenge, all of the control birds showed the typical
clinical signs of infection, including depression, ruffled
feathers, greenish diarrhea, and trembling, and within
5 days post-challenge a 100% mortality rate was ob-
served (Fig. 3A). Post-mortem examination of the
dead birds revealed characteristic lesions of ND such
as petechiae in the proventriculus, white punctate ne-
crosis in the spleen, and hemorrhages in the intestine
and cecal tonsil (Fig. 3b). By contrast, there were no
clinical signs, gross lesions, or mortality even after
14 days post-challenge in vaccinated chickens. At day
5, virus shedding was detected from all of the chickens
that died in all of the unvaccinated groups (3.01–3.64
log10 EID50 /0.1 mL), no NDV shedding was recorded in
group B, and virus shedding was only detected in one of
10 birds in vaccinated groups A (log10 EID50 /0.1 mL
< 1.00) and C (log10 EID50 /0.1 mL = 1.07), as shown
in Table 2.
Fig. 2 Antibody dynamics of vaccinated chickens. Three-week-old
chickens were immunized by subcutaneous injection with the
developed inactivated vaccine (NDV, aSG10 and H9N2, G). The mean
HI titers for sera collected weekly for 15 weeks post-vaccination
are shown
Fig. 3 a Survival of chickens after challenge with NDV strains isolated in 2012–2014. b Gross lesions in the cecal tonsil, spleen, duodenum, and
glandular stomach of dead chickens
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Protective efficacy against LPAI H9N2
To evaluate the efficacy of the inactivated vaccine
against prevalent H9N2 viruses, three selected viruses
were used for the challenge test. When challenged with
H9N2, no specific clinical signs were observed, with the
exception of one bird from each of the control groups J
and K, which exhibited signs of depression and death oc-
curred at 6 days post-inoculation. Virus was detected in
all of the chickens in the control groups at day 5. No
virus shedding was recorded in any of the vaccinated
groups (Table 3).
Discussion
In China, virulent NDV genotype VII first emerged in
the 2000s [23, 24], and strains recently isolated from
chickens have also been shown to belong to this geno-
type. Recent studies and our present results show that
isolates from this prevalent genotype differ from the
widely used vaccine strain LaSota and B1 in the immune
responses they evoke [8, 24]. Therefore, antigenic differ-
ences between the prevalent circulating genotype and
vaccine strains might account for the current ND out-
breaks in vaccinated poultry flocks [25]. To tackle this
problem, new vaccines that better match circulating vi-
ruses have been developed [23, 26]. The current study
therefore aimed to develop an NDV vaccine strain that
is immunogenic and safe for use in chickens.
Vaccination is an effective way to prevent and control
the spread of H9N2 AIVs, but the current vaccine used
in China is prepared from isolates that were circulating
in the early 1990s, and their protective efficacy has been
decreasing in recent years. A HI test showed that the
commercial vaccine strain SS/94 does not provide robust
protection against emerging H9N2 AIVs in China [22].
It is therefore crucial that novel candidate vaccine
strains are employed to combat emerging H9N2 AIVs in
China. Previous phylogenetic analysis of the HA genes
of H9N2 AIVs isolated in China between 2010 and 2014
demonstrated that group III, as an emerging lineage, has
become one of the dominant clades. Increasing evidence
suggests that the antigenic drift of field H9N2 AIV in
China is a result of the incomplete protection offered by
the commercial vaccine, probably caused by the persist-
ent prevalence of H9N2 AIV. Our results also highlight
that the currently used vaccine strain should be regularly
evaluated and updated to achieve optimal protection
against AIV infections [21].
According to previous phylogenetic analyses, most
NDVs isolated in 2010–2014 belonged to genotype VII
and most H9N2 AIVs belonged to subgroup III in the
Table 2 Immune protection against NDV isolated in 2012–2014
Virus for
challenge








NDV-HB12 A 7.7 0/10 0/10 1/10b <10-1.00 90
D 0.0 5/5 5/5 5/5 10-3.01 0
NDV-SD13 B 7.3 0/10 0/10 0/10 ND 100
E 0.0 5/5 5/5 5/5 10-3.52 0
NDV-HB14 C 7.5 0/10 0/10 1/10 10-1.07 90
F 0.0 5/5 5/5 5/5 10-3.64 0
- M 0.0 0/5 0/5 0/5b,c ND 100
ND no data
aProtection definition: means survival without signs of clinical disease not shedding
bCloaca swab
cThroat swab
Table 3 Immune protection against H9 AIV isolated in 2012–2014
Virus for challenge Group HI titer (log2) Clinical signs/total Deaths/total Positive swabs/total Protection rate (%)a
H9-JS12 G 9.2 0/10 0/10 0/10c 100
J 0.0 1/5 1/5 5/5 0
H9-HB13 H 9.3 0/10 0/10 0/10 100
K 0.0 1/5 1/5 5/5 0
H9-SD14 I 8.7 0/10 0/10 0/10 100
L 0.0 0/5 0/5 5/5 0
- M 0.0 0/5 0/5 0/5b,c 100
aProtection definition: means survival without signs of clinical disease not shedding
bCloaca swab
cThroat swab
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BJ/94-like clade, a predominant genotype. These strains
showed high homology to each other and a lower level
of homology to traditional vaccine strains in China. In
this study, a new inactivated vaccine was developed
based on the prevalent NDV and H9N2 AIV strains
(NDV aSG10 and H9N2 G) and its efficacy was evalu-
ated in chickens [27, 28].
Evaluation of NDV or AIV vaccine immunogenicity is
largely based on HI antibody titers. In this study, the HI
antibody titers of all chickens vaccinated with the inacti-
vated vaccine were detected at weekly intervals until 15
wpv by the HI test. The results indicated that the vac-
cine could induce a fast immunological reaction and the
mean HI titers were over 6.9 log2 against both NDV and
H9N2 AIV at 2 wpv. At 4 wpv, peak levels of HI anti-
bodies were detected with a mean HI titer of 8.6 log2
against NDV and 9.5 log2 against H9N2. Antibody titers
of more than 6.0 log2 were detected up until at least 15
wpv. The results suggested that this new inactivated vac-
cine was significantly more effective at generating HI
antibody responses than the traditional vaccine strain.
We next evaluated whether vaccination of chickens
with the inactivated NDV and H9N2 vaccine could re-
duce the disease rates of both endemic NDV and H9N2
viruses in China by challenge test. We challenged the
birds via the injection route in order to the birds receive
actual dose of challenge viruses. We also tried a natural
route for NDV and H9N2 in our previous studies and
the birds demanded higher HI antibodies to obtain good
protection [28, 29]. Reduced mortality rates and de-
creased viral shedding were detected. Unvaccinated
chickens challenged with NDV showed a 100% mortality
rate and high levels of virus shedding of 3.01–3.64 log10
EID50/0.1 mL, compared with no mortality and a lower
rate of viral shedding of 0–1.07 log10 EID50/0.1 mL in
vaccinated groups. All of the unvaccinated chickens
challenged with H9N2 shed virus, whereas no virus
shedding was detected in vaccinated groups.
Conclusion
Our results showed that the inactivated NDV and H9N2
vaccine (strain NDV aSG10 and H9N2 G) induces a high
and prolonged immune response in vaccinated chickens
and good protection efficacy against prevalent viruses.
This novel vaccine could therefore potentially be used in
the poultry industry to prevent and control ND and
H9N2 influenza in chickens in China.
Methods
Animals
All SPF chicken eggs and chickens were purchased from
Merial Vital Laboratory Animal Technology Co., Ltd
(Beijing, China). The chickens were kept in isolators at
China Agricultural University throughout the experiment
and the animal rearing facilities were approved by the
Beijing Administration Committee of Laboratory Animals
under the leadership of the Beijing Association for Science
and Technology (approval ID SYXK [Jing] 2013–0013).
Vaccine viruses
The selected NDV candidate was strain Chicken/China/
Shandong/aSG10/2010 (abbreviated as aSG10) of geno-
type VIId, which was an attenuated form of the virulent
strain SG10 isolated from an outbreak of ND in chickens
with an intracerebral pathogenicity index (ICPI) of 1.89
and a mean death time of 45 h [29]. The selected H9N2
AIV candidate was strain A/chicken/Hebei/G/2012
(abbreviated as G) of BJ/94 (subgroup III), which was
isolated from a vaccinated breeder broiler flock in 2012
in northern of China.
Challenge viruses
HA gene segments of 19 H9N2 viruses and F gene seg-
ments of 11 NDVs isolated in China from 2012 to 2014
were sequenced as described previously [21, 27]. Multiple
sequence alignment was conducted using the Clustal W
program of the MEGA 5.1 software. A phylogenetic tree
was constructed using the neighbor-joining method with
1000 bootstrap replicates using the MEGA 5.1 software.
According to phylogenetic analyses, three NDV and H9N2
virus isolates were chosen for challenge experiments.
Biological characterization of the viruses
Each virus was amplified in 10-day-old SPF embryonated
chicken eggs, and the virus titer (EID50) was determined
and calculated by the Reed–Muench method [30] based
on a hemagglutination assay of the allantoic fluid of eggs
inoculated with 10-fold serial dilutions of viruses. The
virulence of the viruses was evaluated using standard
pathogenicity tests, the ICPI [31] for NDVs, and the
IVPI [6] for H9N2 AIVs.
Vaccine development
NDV strains aSG10 and H9N2 G were propagated in the
allantoic cavities of 10-day-old SPF embryonated chicken
eggs. Allantoic fluid was harvested 72–96 h after inocu-
lation, and the virus titer in the allantoic fluid of 108.50
EID50/0.1 mL for two virus was used for antigen produc-
tion. The egg-derived virus was inactivated with formalin
at 37 °C at a final concentration of 0.1% for 18 h for
NDV aSG10 or 0.2% for 24 h for H9N2 G. Complete
inactivation of the virus was confirmed through three
passages in 10-day-old embryonated SPF chicken eggs.
To produce the vaccine, the inactivated viral antigens
were blended at a ratio of 1:1 (V/V), then mixed with oil
emulsion adjuvants Marcol 52 (Seppic, Paris, France) at
a ratio of 1:2 (V/V).
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Efficacy experiment
Dynamics of HI antibody
Forty 3-week-old SPF While Leghorn chickens were di-
vided into two groups and 20 for each. The birds in
Group 1 were vaccinated with one single dose (0.25 mL/
bird) of the inactivated vaccine via subcutaneous injec-
tion. Group 2 was the control. Blood was collected from
each group (n = 10) at weekly intervals until 15 weeks
post-vaccination (wpv). Serum was separated and stored
at −20 °C until use. The antibody titers were determined
by HI tests using 1% chicken red blood cells according
to the OIE recommended protocol [32]. The HI titers
were expressed as the log2 of the reciprocal of the high-
est serum dilution, resulting in complete inhibition of
red blood cells.
Challenge of vaccinated chickens with LPAI H9N2 and
virulent NDV
SPF chickens were challenged with one of three LPAI
H9N2 avian influenza viruses or one of three virulent
NDV challenge strains three weeks after vaccination and
observed for clinical disease and shedding for two weeks
after challenge. A total of 95, 3-week-old, SPF chickens
were randomly divided into 13 groups (A–M) and
treated as shown in Table 4. In brief, six groups (A–C
and G–I, n = 10) were injected subcutaneously with one
single dose (0.25 mL/bird) of the inactivated vaccine, an-
other seven unimmunized groups served as challenged
controls (D–F and J–L, n = 5) and unchallenged controls
(M, n = 5). Chickens of six immunized groups and six
control groups were infected with 105.0 EID50 for NDV
(Intramuscular injection) and 106.0 EID50 for H9N2
(Intravenous injection) at 3 wpv. Chickens were moni-
tored daily for morbidity and mortality for 14 days.
Virus isolation and titration
To determine viral shedding from individual chickens,
cloacal or throat swabs were obtained at 5 days post-
challenge for virus isolation in eggs. Swab samples were
suspended in 1.0 mL of PBS supplemented with penicillin-
streptomycin (10,000 IU/mL) and then inoculated into 10-
day-old embryonated chicken eggs (n = 3 eggs/sample)
through the intra-allantoic route. The allantoic fluid was
harvested at 5 days post-inoculation and checked for NDV
and H9 AIV growth by a HA test using 1% chicken red
blood cells. Positive samples were further titrated by EID50
determination in 10-day-old embryonated chicken eggs.
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